Cover Image

HARDBACK
$69.95



View/Hide Left Panel

Table 107. Adverse events reported in RCTs

Author Year

N enrolled

Vit D dose (IU/d)

Ca dose (mg/d)

Duration

Adverse Event data (n=case#)

Yamamoto 1995117

471

0

1000

6 mo

Comparing calcium group to the placebo group, excessive gas and bloating were more frequently reported by white women at 3 months and by whites, in general, at 6 months, and white men reported more loose stools at 6 months.

Moschonis 2006215

112

300 D3

600 or 1200

12 mo

Bloating, constipation and intestinal discomfort apparently related to the calcium supplement

Bunout 200680

96

400

800

9 mo

Adverse events that required hospital admission:

 

 

 

 

 

Vit D plus exercise training group (n=3): retrosternal pain, a non-ST elevation myocardial infarction and a transient ischemic attack.

 

 

 

 

 

Calcium, Vit D plus exercise training group (n=1): acute cholecystitis

Wactawski-Wende 200671

36282

400

1000

7 y

The WHI trial found an increase in the risk of renal stones (Hazard Ratio 1.17 95% CI 1.02, 1.34), corresponding to 5.7 events per 10,000 person years of exposure.

Burleigh 200781

205

800 D3

1200

Median 1 mo

Hypercalcemia (n=2)

Lappe 2008208

5201

800

200

8 wks

GI disruption such as constipation, diarrhea, upset stomach (4%), and musculoskeletal soreness (0.9%)

Brooke 198034

126

1000

0

3rd trimester only

Vit D group (craniotabes, n=2), placebo group (hypocalcemia, n=5; craniotabes, n=6)

Lappe 200752

1180

1000 D3

1400-1500

4 y

Renal calculi in placebo (n=1), renal calculi in calcium only (n=3), renal calculi in calcium plus vit D (n=1)

Mastaglia 2006240

65

5000 or 10,000 D2

500

3 mo

Hypercalciuria (n=1) in control group

Zhu 200898

256

1000 D2

1200

12 mo

There were no significant differences between the vitamin D and the control groups in the rate of incident cancer and vascular disease (ischemic heart disease and stroke).

 

 

 

 

 

There were 8 and 5 adverse events in vitamin D and the control groups, respectively. One participant in the vitamin D group had mild asymptomatic hypercalcemia one occasion. No case of renal calculus was reported.

 

 

 

 

 

1 participant was deceased during the study.

Sneve 200850

445

Group 1: 2 capsules of vitamin D3 each 20,000 IU taken twice a week (Monday and Thursday): ~5714 IU/d

Group 2: 1 capsules of vitamin D3 each 20,000 IU taken twice a week (Monday and Thursday): ~2857 IU/d

500

12 mo

Primary hyperparathyroidism (n=2), increase in serum calcium to 2.62 mmol/L (n=1), transient increases in serum calcium > 2.59 mmol/L (n=4).

 

 

 

 

317 other adverse events were recorded, most of them related to GI discomfort. There were no significant differences between the treatment groups regarding adverse events.



The National Academies of Sciences, Engineering, and Medicine
500 Fifth St. N.W. | Washington, D.C. 20001

Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement